Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3OTHER 1NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 2NET 1Gynecologic 1Endocrine 1

Conditions

Small Cell Lung Carcinoma 62Leukemia, Myeloid, Acute 14Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 10Lymphoma, Non-Hodgkin 9Lymphoma, Large B-Cell, Diffuse 9Recurrence 8Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 6Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Ovarian Neoplasms 3Leukemia 3Hodgkin Disease 3Extensive Stage Small Cell Lung Cancer 3Carcinoma, Small Cell 3Small Cell Lung Cancer Extensive Stage 2SCLC 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoma, B-Cell 2Lymphatic Diseases 2Immunoproliferative Disorders 2Hematologic Diseases 2Glioblastoma 2Ependymoma 2Advanced Solid Tumors 2Widespread Small Cell Lung Cancer 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Cisplatin 5Pemetrexed 3Etoposide 3pembrolizumab 2belinostat 2RRx-001 2Carboplatin 2vosaroxin 1taxane 1sagopilone 1pomalidomide 1lurtotecan 1liposomal doxorubicin 1etoposide phosphate 1enzalutamide 1abiraterone 1Vinorelbine 1Rhenium 1Radiation 1Quality of Life 1Patient Reported Outcome Measures 1Paclitaxel 1PT-100 dipeptide 1Molecular Diagnostic Techniques 1Irinotecan 1Immunotherapy 1Gemcitabine 1GSK2879552 1Fluorouracil 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Small Cell × Etoposide × Clear all
NCT02489903 2025-03-17

RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)

EpicentRx, Inc.

Phase 2 Completed
139 enrolled 14 charts
EndocrineGynecologicNETThoracic

Carcinoma, Ovarian Epithelial, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Carcinoma, Small Cell, Neuroendocrine Tumors

NCT03699956 2024-03-26

REPLATINUM

EpicentRx, Inc.

Phase 3 Terminated
18 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

NCT00537511 2019-11-19

A Phase I/II Study to Determine the Maximum Tolerated Dose (MTD) and Safety of CC-4047 (Pomalidomide) Administered in Conjunction With Cisplatin and Etoposide

Celgene

Phase 1/2 Terminated
22 enrolled 13 charts

Carcinoma, Small Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡